Immunocore Holdings PLC ADR IMCR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $27.90
- Day Range
- $27.59–29.00
- 52-Week Range
- $27.56–40.71
- Bid/Ask
- $28.54 / $31.48
- Shares Outstanding
- 50.87M
- Market Cap
- $1.46B
- Volume/Avg
- 412,681 / 395,929
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.50
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 524
- Website
- https://www.immunocore.com
Valuation
|
Metric
|
IMCR
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.68 |
Price/Sales | 3.50 |
Price/Cash Flow | 216.68 |
Price/Earnings
IMCR
Financial Strength
|
Metric
|
IMCR
|
|---|---|
Quick Ratio | 3.86 |
Current Ratio | 4.18 |
Interest Coverage | −1.18 |
Quick Ratio
IMCR
Profitability
|
Metric
|
IMCR
|
|---|---|
Return on Assets (Normalized) | −1.77% |
Return on Equity (Normalized) | −4.88% |
Return on Invested Capital (Normalized) | −2.57% |
Return on Assets
IMCR
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Qtnxsjf | Rjgbb | $111B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Znvcwzrgf | Wkcrmq | $63B | |||
| argenx SE ADR
ARGX
| Jhnpywjb | Hjq | $55B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Prksqsr | Hjsdjt | $39B | |||
| Royalty Pharma PLC Class A
RPRX
| Wbkwbrjtb | Zxystyz | $24B | |||
| BioNTech SE ADR
BNTX
| Hsxjfgft | Yybc | $22B | |||
| Incyte Corp
INCY
| Vgdfwly | Phklp | $21B | |||
| Moderna Inc
MRNA
| Jgdlztck | Fcwz | $18B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Xxnzdrzp | Xjqm | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Nxkgdxlfv | Rvqbg | $13B |
United States